The role of NOX2-produced ROS was also confirmed both by the genetic deletion of NOX2 in the mouse model of prostate cancer, resulting in reduced angiogenesis and an almost complete failure in tumor development, and by NOX2 pharmacological inhibition that suppressed established prostate tumors in mice [66]. The gene discussed is CYBB; the disease is prostate cancer.